Dr. Edward E. Kimbrough, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Medical University of South Carolina College of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 693
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: Medical University of South Carolina College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
SC license 19738
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Prisma Health Richland Hospital Columbia, SC
- Lexington Medical Center West Columbia, SC
- Prisma Health Baptist Columbia, SC
- Musc Health Columbia Medical Center Downtown Columbia, SC
- Kershawhealth Camden, SC
Medical groups
- Columbia Gastroenterology Associates PA (10 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 693
- Services billed
- 1,969
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Pathology examination of tissue using a microscope, intermediate complexity | 461 | 228 |
| Established patient office or other outpatient visit, 20-29 minutes | 216 | 172 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 197 | 195 |
| New patient office or other outpatient visit, 30-44 minutes | 104 | 104 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 83 | 83 |
| Special stained specimen slides to examine tissue including interpretation and report | 75 | 49 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 69 | 69 |
| Established patient office or other outpatient visit, 30-39 minutes | 69 | 61 |
| Biopsy of large bowel using a flexible endoscope | 64 | 64 |
| New patient office or other outpatient visit, 45-59 minutes | 52 | 52 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Columbia, SC | 286 |
| Pantoprazole Sodium Other prescribers in Columbia, SC | 230 |
| Dicyclomine Hcl Other prescribers in Columbia, SC | 130 |
| Linzess (linaclotide) Other prescribers in Columbia, SC | 85 |
| Gavilyte-C (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Columbia, SC | 71 |
| Omeprazole Other prescribers in Columbia, SC | 57 |
| Famotidine Other prescribers in Columbia, SC | 46 |
| Dexlansoprazole Dr (dexlansoprazole) Other prescribers in Columbia, SC | 45 |
| Sucralfate Other prescribers in Columbia, SC | 45 |
| Diphenoxylate-Atropine (diphenoxylate hcl/atropine) Other prescribers in Columbia, SC | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 145 payments worth $2,590 in total to this clinician.
| AbbVie Inc. | $799 |
|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $236 |
| Ardelyx, Inc. | $227 |
| Janssen Biotech, Inc. | $168 |
| Pfizer Inc. | $149 |
| Regeneron Healthcare Solutions, Inc. | $146 |
| Qol Medical, LLC | $143 |
| Genzyme Corporation | $130 |
| Food and Beverage | $2,590 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $346,841 in research payments for these studies, mostly to the institutions running them.
- Roche Cancer Screening Collection Study
Genentech, Inc. - A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH - A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/…
Boehringer Ingelheim International GmbH - Study of DONQ52 in Active Celiac Disease
Chugai Pharmaceutical Co., Ltd.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.